PharmaShots

In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and…

Jun 2019

TOP 20

Top 20 Medical Device Companies Based on 2018 Revenue

The Medical device market is growing with greater needs of patients and with their emerging diseases. 2018 has shown major advancement in medical device needs and upgrades with 55 novel…

Jun 2019

INSIGHTS+

Insights+ Key Biosimilars Events of May 2019

Biosimilars are going in market with vast emerging needs of people for multiple diseases. The biologics that are too costly to be used in the markets. Hence physicians are developing…

May 2019

TOP 20

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top…

May 2019

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2018

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to…

May 2019

TOP 20

Top 20 BioPharma Companies based on 2018 Total Revenue

The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major…

Mar 2019

INSIGHTS+

PharmaShots Awarded as Feedspot’s Top 50 Pharma Blog

Shots:Team PharmaShots proudly announce that we are awarded as Top 50 Pharma Blog by FeedspotWe are thankful to Feedspot for identifying our efforts and awarding us with this honor. We…

Mar 2019

INSIGHTS+

Insights+: The US FDA New Drug Approvals in 2018

1. Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)Published: 14 Feb,2018 | Tags: Janssen, Erleada, apalutamide, Receives, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, NM-CRPC2. Helsinn's (fosnetupitant + palonosetron)…

Jan 2019

INSIGHTS+

PharmaShots Year in Review: Biosimilars Approvals in 2018

THE US FDA APPROVALS 1. Pfizer's Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for AnemiaPublished: 15 May, 2018 | Tags: Pfizer, Retacrit, epoetinalfa-epbx, biosimilar, Receives, FDA, Approval, Anemia2. Pfizer's Nivestym (filgrastim-aafi, biosmilar) Receives…

Jan 2019

INSIGHTS+

PharmaShots’ Most Read News of 2018

PharmaShots' Most Read News of 2018 | Top 10 Pharma News of 2018 1. Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology PortfolioPublished: 22 Jan, 2018 | Tags:…

Insights+: An Analysis of Biopharma Companies Growth in Last 20 Years (1999-2018)

Top 20 Medical Device Companies Based on 2018 Revenue

Insights+ Key Biosimilars Events of May 2019

Top 10 Oncology Companies By 2018 Revenue

Insights+: Breakthrough Therapy Designation by the US FDA in 2018

Top 20 BioPharma Companies based on 2018 Total Revenue

PharmaShots Awarded as Feedspot’s Top 50 Pharma Blog

Insights+: The US FDA New Drug Approvals in 2018

PharmaShots Year in Review: Biosimilars Approvals in 2018

PharmaShots’ Most Read News of 2018

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter